Document is current
Any future updates will be listed below
-
Authors
Fang, Xuefeng
Zhong, Chenhan
Weng, Shanshan
Hu, Hanguang
Wang, Jian
Xiao, Qian
Wang, Jianwei
Sun, Lifeng
Xu, Dong
Liao, Xiujun
Dong, Caixia
Zhang, Suzhan
Li, Jun
Ding, Kefeng
Yuan, Ying
-
Funding
Funding for this research was provided by:
Provincial Key R&D Program of Zhejiang Province (2021C03125)
National Natural Science Foundation of China (81872481)
- License Information
-
More Information
Article History
Received: 7 March 2023
Accepted: 30 June 2023
First Online: 18 July 2023
Declarations
:
: The study (Protocol version 3.0, June 15th 2021) was approved by the Ethics Committee of the Second Affiliated Hospital of Zhejiang University School of Medicine (NO.2021–0720) and registered at Clinicaltrials.gov (NCT05171660) with the name “Combination With Sintilimab and XELOX + Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer”. The study protocol has been approved by all participant centers. The principal investigator is responsible for submitting the protocol amendments and changes to the informed consent document to the Institutional Review Board(s) and/or Independent Ethics Committee(s) at each center and obtaining their approval where necessary. If substantial amendments to the protocol and other relevant study documents are required, the principal investigator will ensure that they are implemented only after approval by the relevant regulatory authorities. The Human Ethics Committee of the Second Affiliated Hospital of the Zhejiang University School of Medicine has granted central ethical approval. All personnel involved in conducting the current study shall abide by the latest Declaration of Helsinki and Ethical Guidelines for Clinical Studies. Written informed consent will be obtained from all participants to the BBCAPX study.
: Not applicable.
: The authors declare no competing interests.
